Publications by authors named "M Mutlu Meydanli"
Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
Eur J Cancer
November 2024
Aim: The aim of this study was to assess whether the use of sentinel lymph node (SLN) in addition to lymphadenectomy was associated with survival benefit in patients with early-stage cervical cancer.
Methods: International, multicenter, retrospective study.
Inclusion Criteria: cervical cancer treated between 01/2007 and 12/2016 by surgery only; squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, FIGO 2009 stage IB1-IIA2, negative surgical margins, and laparotomy approach.
Article Synopsis
- The study aimed to evaluate the effects of adjuvant treatments and factors affecting recurrence and survival in patients with stage IIB endometrial cancer, using data from surgeries performed in Turkey between 2005 and 2022.
- Out of 7323 patients, 565 were identified as stage IIB; most received adjuvant radiotherapy, but the study found no significant survival benefits from adjuvant treatments overall.
- Notably, patients with tumors larger than 4 cm and myometrial invasion greater than 50% had higher recurrence rates, while adjuvant treatment improved overall survival only for those with deep myometrial invasion.
Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
Am J Obstet Gynecol
October 2023
Background: International guidelines recommend tailoring the radicality of hysterectomy according to the known preoperative tumor characteristics in patients with early-stage cervical cancer.
Objective: This study aimed to assess whether increased radicality had an effect on 5-year disease-free survival in patients with early-stage cervical cancer undergoing radical hysterectomy. The secondary aims were 5-year overall survival and pattern of recurrence.
Objective: The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer.
View Article and Find Full Text PDF